Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1987 Jun;31(6):876–882. doi: 10.1128/aac.31.6.876

Ampicillin versus cefamandole as initial therapy for community-acquired pneumonia.

D J Weber, S B Calderwood, A W Karchmer, J E Pennington
PMCID: PMC284203  PMID: 3304156

Abstract

One hundred seven patients with community-acquired pneumonia thought to be of bacterial etiology by the admitting physician but whose initial sputum Gram stain was inadequate to direct specific therapy were randomized to receive either intravenous ampicillin or cefamandole as empiric therapy. Patients were excluded if the initial sputum Gram stain was highly suggestive of infection with Streptococcus pneumoniae, Staphylococcus aureus, or an enteric gram-negative bacillus. The two study groups had comparable demographic and presenting clinical features. The mean age of the patients evaluable for determination of clinical efficacy was 69 years, and greater than 75% had at least one serious underlying medical disorder. In the 90 evaluable patients, there were 11 therapeutic failures (12%), including 5 deaths (5%). Cefamandole, a broad-spectrum antibiotic, was not more efficacious than ampicillin in producing a satisfactory clinical response or in shortening the duration of parenteral therapy. Patients received an average of only 4 days of intravenous antibiotics before changeover to oral therapy and were hospitalized for a mean of 7 days. No patient experienced a relapse of pneumonia following successful completion of parenteral drug therapy. We conclude that cefamandole is not a more effective agent than ampicillin for empiric therapy of community-acquired bacterial pneumonia of uncertain etiology.

Full text

PDF
876

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bentley D. W. Bacterial pneumonia in the elderly: clinical features, diagnosis, etiology, and treatment. Gerontology. 1984;30(5):297–307. doi: 10.1159/000212649. [DOI] [PubMed] [Google Scholar]
  2. Berk S. L., Holtsclaw S. A., Kahn A., Smith J. K. Transtracheal aspiration in the severely ill elderly patient with bacterial pneumonia. J Am Geriatr Soc. 1981 May;29(5):228–231. doi: 10.1111/j.1532-5415.1981.tb01772.x. [DOI] [PubMed] [Google Scholar]
  3. Berntsson E., Blomberg J., Lagergård T., Trollfors B. Etiology of community-acquired pneumonia in patients requiring hospitalization. Eur J Clin Microbiol. 1985 Jun;4(3):268–272. doi: 10.1007/BF02013650. [DOI] [PubMed] [Google Scholar]
  4. Beumer H. M., Olislagers W. P., Kahn M., van Hamersveld J. D. Clinical evaluation of cefotiam and cefamandole in respiratory tract infections. Int J Clin Pharmacol Ther Toxicol. 1985 Feb;23(2):105–108. [PubMed] [Google Scholar]
  5. Campos J., Garcia-Tornel S., Sanfeliu I. Susceptibility studies of multiply resistant Haemophilus influenzae isolated from pediatric patients and contacts. Antimicrob Agents Chemother. 1984 Jun;25(6):706–709. doi: 10.1128/aac.25.6.706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Crofton J. The John Barnwell Lecture. The chemotherapy of bacterial respiratory infections. Am Rev Respir Dis. 1970 Jun;101(6):841–859. doi: 10.1164/arrd.1970.101.6.841. [DOI] [PubMed] [Google Scholar]
  7. Delgado D. G., Brau C. J., Cobbs C. G., Dismukes W. E. Clinical and laboratory evaluation of cefamandole in the therapy of Haemophilus spp. Bronchopulmonary infections. Antimicrob Agents Chemother. 1979 Jun;15(6):807–812. doi: 10.1128/aac.15.6.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Doern G. V., Jorgensen J. H., Thornsberry C., Preston D. A. Prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae: a collaborative study. Diagn Microbiol Infect Dis. 1986 Feb;4(2):95–107. doi: 10.1016/0732-8893(86)90143-4. [DOI] [PubMed] [Google Scholar]
  9. Dorff G. J., Rytel M. W., Farmer S. G., Scanlon G. Etiologies and characteristic features of pneumonias in a municipal hospital. Am J Med Sci. 1973 Nov;266(5):349–358. doi: 10.1097/00000441-197311000-00002. [DOI] [PubMed] [Google Scholar]
  10. Ebright J. R., Rytel M. W. Bacterial pneumonia in the elderly. J Am Geriatr Soc. 1980 May;28(5):220–223. doi: 10.1111/j.1532-5415.1980.tb00523.x. [DOI] [PubMed] [Google Scholar]
  11. Engle J. C., Lifland P. W., Schleupner C. J. Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia. Antimicrob Agents Chemother. 1985 Jul;28(1):146–148. doi: 10.1128/aac.28.1.146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fekety F. R., Jr, Caldwell J., Gump D., Johnson J. E., Maxson W., Mulholland J., Thoburn R. Bacteria, viruses, and mycoplasmas in acute pneumonia in adults. Am Rev Respir Dis. 1971 Oct;104(4):499–507. doi: 10.1164/arrd.1971.104.4.499. [DOI] [PubMed] [Google Scholar]
  13. Fiala M. A study of the combined role of viruses, mycoplasmas and bacteria in adult pneumonia. Am J Med Sci. 1969 Jan;257(1):44–51. doi: 10.1097/00000441-196901000-00005. [DOI] [PubMed] [Google Scholar]
  14. File T. M., Jr, Tan J. S., Gardner W. G., Baird I. Cefoperazone versus cefamandole in the treatment of acute bacterial lower respiratory tract infections. J Antimicrob Chemother. 1983 Jan;11(1):75–82. doi: 10.1093/jac/11.1.75. [DOI] [PubMed] [Google Scholar]
  15. Garb J. L., Brown R. B., Garb J. R., Tuthill R. W. Differences in etiology of pneumonias in nursing home and community patients. JAMA. 1978 Nov 10;240(20):2169–2172. [PubMed] [Google Scholar]
  16. Garibaldi R. A. Epidemiology of community-acquired respiratory tract infections in adults. Incidence, etiology, and impact. Am J Med. 1985 Jun 28;78(6B):32–37. doi: 10.1016/0002-9343(85)90361-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Grieco M. M., Lange M., Daniels J. A., Den M., Amaram N., Kornfeld H. Single-blind controlled study of ceftizoxime and cefamandole in the treatment of community-acquired pneumonia. J Antimicrob Chemother. 1982 Nov;10 (Suppl 100):223–225. doi: 10.1093/jac/10.suppl_c.223. [DOI] [PubMed] [Google Scholar]
  18. Kalinske R. W., Parker R. H., Brandt D., Hoeprich P. D. Diagnostic usefulness and safety of transtracheal aspiration. N Engl J Med. 1967 Mar 16;276(11):604–608. doi: 10.1056/NEJM196703162761103. [DOI] [PubMed] [Google Scholar]
  19. Karnad A., Alvarez S., Berk S. L. Pneumonia caused by gram-negative bacilli. Am J Med. 1985 Jul 15;79(1A):61–67. doi: 10.1016/0002-9343(85)90193-7. [DOI] [PubMed] [Google Scholar]
  20. Keeton G. R., Kehoe B., Phillips S. W., Daya H. Ceftazidime and cefamandole in the treatment of pneumonia. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):27–30. doi: 10.1093/jac/12.suppl_a.27. [DOI] [PubMed] [Google Scholar]
  21. Klimek J. J., Ajemian E., Fontecchio S., Gracewski J., Klemas B., Jimenez L. Community-acquired bacterial pneumonia requiring admission to hospital. Am J Infect Control. 1983 Jun;11(3):79–82. doi: 10.1016/0196-6553(83)90117-7. [DOI] [PubMed] [Google Scholar]
  22. LOURIA D. B., BLUMENFELD H. L., ELLIS J. T., KILBOURNE E. D., ROGERS D. E. Studies on influenza in the pandemic of 1957-1958. II. Pulmonary complications of influenza. J Clin Invest. 1959 Jan;38(1 Pt 2):213–265. doi: 10.1172/JCI103791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. La Force F. M. Community-acquired lower respiratory tract infections. Prevention and cost-control strategies. Am J Med. 1985 Jun 28;78(6B):52–57. doi: 10.1016/0002-9343(85)90364-x. [DOI] [PubMed] [Google Scholar]
  24. Larsen R. A., Jacobson J. A. Diagnosis of community-acquired pneumonia: experience at a community hospital. Compr Ther. 1984 Mar;10(3):20–25. [PubMed] [Google Scholar]
  25. LeFrock J. L., Molavi A., Lentnek A. L., Rolston K. V., Chandrasekar P. H., Smith B. R., Kannangara W., Schell R. F., Oaks S. S., Carr B. B. Comparative study of ceftizoxime and cefamandole in the treatment of bronchopulmonary infections. J Antimicrob Chemother. 1982 Nov;10 (Suppl 100):215–221. doi: 10.1093/jac/10.suppl_c.215. [DOI] [PubMed] [Google Scholar]
  26. Lyons R. W., Brock S. M., Lahiri B. Ceftizoxime and cefamandole in adult patients with acute respiratory failure. J Antimicrob Chemother. 1982 Nov;10 (Suppl 100):227–228. doi: 10.1093/jac/10.suppl_c.227. [DOI] [PubMed] [Google Scholar]
  27. Macfarlane J. T., Finch R. G., Ward M. J., Macrae A. D. Hospital study of adult community-acquired pneumonia. Lancet. 1982 Jul 31;2(8292):255–258. doi: 10.1016/s0140-6736(82)90334-8. [DOI] [PubMed] [Google Scholar]
  28. Mandell G. L. Cefamandole treatment of pulmonary infection caused by gram-negative rods. Scand J Infect Dis Suppl. 1980;Suppl 25:107–111. [PubMed] [Google Scholar]
  29. Mattson K., Renkonen O. V., Kohvakka A., Likitalo H. Clinical experience with cefamandole in pneumonia. Scand J Infect Dis Suppl. 1980;Suppl 25:103–106. [PubMed] [Google Scholar]
  30. McKellar P. P. Treatment of community-acquired pneumonias. Am J Med. 1985 Aug 9;79(2A):25–31. doi: 10.1016/0002-9343(85)90257-8. [DOI] [PubMed] [Google Scholar]
  31. Meyers B. R., Wormser G., Gartenberg G., Nicholas P., Hirschman S. Z. Cefamandole: a new cephalosporin for therapy of hospitalized patients with infection. Mt Sinai J Med. 1978 Nov-Dec;45(6):722–728. [PubMed] [Google Scholar]
  32. Mufson M. A., Chang V., Gill V., Wood S. C., Romansky M. J., Chanock R. M. The role of viruses, mycoplasmas and bacteria in acute pneumonia in civilian adults. Am J Epidemiol. 1967 Nov;86(3):526–544. doi: 10.1093/oxfordjournals.aje.a120763. [DOI] [PubMed] [Google Scholar]
  33. Murray P. R., Washington J. A. Microscopic and baceriologic analysis of expectorated sputum. Mayo Clin Proc. 1975 Jun;50(6):339–344. [PubMed] [Google Scholar]
  34. Musher D. M., Kubitschek K. R., Crennan J., Baughn R. E. Pneumonia and acute febrile tracheobronchitis due to haemophilus influenzae. Ann Intern Med. 1983 Oct;99(4):444–450. doi: 10.7326/0003-4819-99-4-444. [DOI] [PubMed] [Google Scholar]
  35. Petty B. G., Smith C. R., Wade J. C., Conrad G. L., Lipsky J. J., Ellner J. J., Lietman P. S. Double-blind comparison of cefamandole and penicillin in pneumococcal pneumonia. Antimicrob Agents Chemother. 1978 Jul;14(1):13–18. doi: 10.1128/aac.14.1.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Prout S., Potgieter P. D., Forder A. A., Moodie J. W., Matthews J. Acute community-acquired pneumonias. S Afr Med J. 1983 Sep 17;64(12):443–446. [PubMed] [Google Scholar]
  37. Rein M. F., Gwaltney J. M., Jr, O'Brien W. M., Jennings R. H., Mandell G. L. Accuracy of Gram's stain in identifying pneumococci in sputum. JAMA. 1978 Jun 23;239(25):2671–2673. doi: 10.1001/jama.239.25.2671. [DOI] [PubMed] [Google Scholar]
  38. Rodriguez J., Vazquez G. J., Bermudez R. H., Luina A., Ronda C. H. A randomized clinical trial of ceftizoxime and cefamandole in the treatment of serious lower respiratory tract infections. J Antimicrob Chemother. 1982 Nov;10 (Suppl 100):209–213. doi: 10.1093/jac/10.suppl_c.209. [DOI] [PubMed] [Google Scholar]
  39. Saginur R., Bartlett J. G. Antimicrobial drug susceptibility of respiratory isolates of Hemophilus influenzae from adults. Am Rev Respir Dis. 1980 Jul;122(1):61–64. doi: 10.1164/arrd.1980.122.1.61. [DOI] [PubMed] [Google Scholar]
  40. Schwarzmann S. W., Adler J. L., Sullivan R. J., Jr, Marine W. M. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969. Arch Intern Med. 1971 Jun;127(6):1037–1041. [PubMed] [Google Scholar]
  41. Sullivan R. J., Jr, Dowdle W. R., Marine W. M., Hierholzer J. C. Adult pneumonia in a general hospital. Etiology and host risk factors. Arch Intern Med. 1972 Jun;129(6):935–942. [PubMed] [Google Scholar]
  42. Thorsteinsson S. B., Musher D. M., Fagan T. The diagnostic value of sputum culture in acute pneumonia. JAMA. 1975 Aug 25;233(8):894–895. [PubMed] [Google Scholar]
  43. Verghese A., Berk S. L. Bacterial pneumonia in the elderly. Medicine (Baltimore) 1983 Sep;62(5):271–285. doi: 10.1097/00005792-198309000-00002. [DOI] [PubMed] [Google Scholar]
  44. Wallace R. J., Jr, Musher D. M., Martin R. R. Hemophilus influenzae pneumonia in adults. Am J Med. 1978 Jan;64(1):87–93. doi: 10.1016/0002-9343(78)90182-1. [DOI] [PubMed] [Google Scholar]
  45. Wallace R. J., Jr, Niefield S. L., Waters S., Waters B., Awe R. J., Wiss K., Martin R. R., Greenberg S. B. Comparative trial of cefonicid and cefamandole in the therapy of community-acquired pneumonia. Antimicrob Agents Chemother. 1982 Feb;21(2):231–235. doi: 10.1128/aac.21.2.231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. White R. J., Blainey A. D., Harrison K. J., Clarke S. K. Causes of pneumonia presenting to a district general hospital. Thorax. 1981 Aug;36(8):566–570. doi: 10.1136/thx.36.8.566. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES